Table 1 Baseline characteristics by bivalent vaccine type
No. (%) | |||
|---|---|---|---|
Characteristic | Total (n = 98) | mRNA-1273 (BA.1) (n = 72) | BNT162b2 (BA.4/BA.5) (n = 26) |
Demographics | |||
Age, median (IQR), y | 70 (61, 77) | 69 (61, 75) | 70 (62, 78) |
Sex (Female) | 34 (35) | 21 (29) | 13 (50) |
Race | |||
Asian | 26 (27) | 20 (28) | 6 (23) |
Black | 7 (7) | 6 (8) | 1 (4) |
Caucasian | 38 (39) | 33 (46) | 5 (19) |
Other/unknown | 27 (28) | 13 (18) | 14 (54) |
Patient type | |||
Dialysis | 83 (85) | 57 (79) | 26 (100) |
Kidney transplant | 15 (15) | 15 (21) | 0 (0) |
Cause of chronic kidney disease | |||
Diabetes | 29 (30) | 22 (31) | 7 (27) |
Glomerulonephritis | 21 (21) | 13 (18) | 8 (31) |
Hypertension | 15 (15) | 11 (15) | 4 (15) |
Other | 33 (33) | 26 (36) | 7 (27) |
Prior COVID-19 (RT-PCR or rapid antigen test) | 25 (26) | 19 (26) | 6 (23) |
Vaccine Type | |||
Dose 1 | |||
ChAdOx1 | 3 (3.1) | 2 (2.8) | 1 (3.8) |
mRNA-1273 | 36 (37) | 35 (49) | 1 (3.8) |
BNT162b2 | 59 (60) | 35 (49) | 24 (92) |
Dose 2 | |||
ChAdOx1 | 3 (3.1) | 2 (2.8) | 1 (3.8) |
mRNA-1273 | 40 (41) | 39 (54) | 1 (3.8) |
BNT162b2 | 55 (56) | 31 (43) | 24 (92) |
Dose 3 | |||
mRNA-1273 | 56 (57) | 45 (62) | 11 (42) |
BNT162b2 | 42 (43) | 27 (38) | 15 (58) |
Dose 4 | |||
mRNA-1273 | 65 (66) | 56 (78) | 9 (35) |
BNT162b2 | 26 (27) | 10 (14) | 16 (62) |
mRNA-1273 Bivalent (BA.1) | 6 (6.1) | 6 (8.3) | 0 (0) |
BNT162b2 Bivalent (BA.4/BA.5) | 1 (1.0) | 0 (0) | 1 (3.8) |
Dose 5 | |||
mRNA-1273 Bivalent (BA.1) | 66 (73) | 66 (100) | 0 (0) |
BNT162b2 Bivalent (BA.4/BA.5) | 24 (27) | 0 (0) | 24 (100) |
Bivalent vaccine dose number | |||
Dose 4 | 8 (8.2) | 3 (4.1) | 5 (20) |
Dose 5 | 90 (92) | 70 (96) | 20 (80) |
Comorbidities | |||
Chronic obstructive pulmonary disease | 8 (8.2) | 5 (6.9) | 3 (12) |
Coronary artery disease | 14 (14) | 7 (9.7) | 7 (27) |
Congestive heart failure | 15 (15) | 10 (14) | 5 (19) |
Cerebrovascular disease | 10 (10) | 7 (9.7) | 3 (12) |
Hypertension | 80 (82) | 55 (76) | 25 (96) |
Malignancy | 9 (9.7) | 7 (9.7) | 2 (9.5) |
Peripheral vascular disease | 8 (8.2) | 6 (8.3) | 2 (7.7) |
Immunosuppression | 17 (17) | 16 (22) | 1 (3.8) |
Prednisone | 16 (16) | 15 (94) | 1 (100) |
Mycophenolic acid | 12 (12) | 12 (75) | 0 (0) |
Calcineurin inhibitor | 16 (16) | 16 (100) | 0 (0) |
